<DOC>
	<DOCNO>NCT00925821</DOCNO>
	<brief_summary>Subjects age 65 year newly diagnose multiple myeloma require treatment eligible . Minimal pretreatment ( 2 cycle chemotherapy ; local irradiation ; surgery ) permit . After enrollment , patient receive four cycle RAD induction treatment : combination lenalidomide ( Revlimid ) , adriamycin , dexamethasone . If least minimal response achieve RAD , undergo chemomobilization ( cyclophosphamide , etoposide ) peripheral blood stem cell one uniform cycle high-dose melphalan chemotherapy follow first stem cell transplant . If high-risk feature ( elevated beta 2-microglobulin , adverse cytogenetic factor , elevate LDH , Ig A isotype ) present diagnosis , patient allocate consolidative allogeneic transplant follow dose-reduced conditioning . If appropriate donor available , patient consent lack high-risk feature second autograft follow high-dose melphalan deliver . All patient proceed lenalidomide maintenance ( one year ) follow hematopoietic reconstitution .</brief_summary>
	<brief_title>Lenalidomide-Adriamycin-Dexamethasone ( RAD ) Induction Followed Stem Cell Transplant Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Written inform consent Newly diagnose multiple myeloma Maximum one prior systemic therapy ( 2 cycle ) Presence CRAB criterion Measurable disease parameter Left ventricular ejection fraction least 55 % DLCO least 60 % Adequate bone marrow function Use adequate contraception female subject childbearing potential male subject Eligible autologous allogeneic stem cell transplantation Bone marrow baseline sample evaluable interphase cytogenetics Any serious medical condition prevent subject write informed consent Progressive disease ( PD ) initial treatment Pregnant lactating female Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data Use experimental drug therapy within 28 day baseline Preexisting neuropathy ≥ grade 2 severity Known hypersensitivity thalidomide Any prior use lenalidomide Positive HIV infectious hepatitis , type A , B C serologic test Serum creatinine despite induction therapy ≥ 2.0 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Allogeneic stem cell transplantation</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>IMiD</keyword>
</DOC>